⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10359801 | 0.69 | — | — | |
| SCHEMBL2077291 | 0.67 | — | — | |
| SCHEMBL1119064 | 0.64 | — | — | |
| SCHEMBL767312 | 0.61 | — | — | |
| Water SCHEMBL27581439 | 0.61 | ALDH1A1 (0.50) | — | |
| SCHEMBL766221 | 0.61 | — | — | |
| SCHEMBL9138097 | 0.61 | — | — | |
| SCHEMBL11819596 | 0.61 | — | — | |
| Ammonia Solution, Strong SCHEMBL11815178 | 0.59 | — | — | |
| SCHEMBL1863210 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225327-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3902805-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV Therapeutics Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3902801-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV Therapeutics Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020140052-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140053-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140055-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2004006914-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030236297-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| US-20030220345-A1 | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones | HAMBY JAMES MARINO (US) | 2003-11-27 | — | — | US | disclosed |
| US-20030186973-A1 | 2-Thia-1,6,8-Triaza-Naphthalene-2,2-Dioxides are kinase inhibitors | REPINE JOSEPH THOMAS (US) | 2003-10-02 | — | — | US | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003062246-A1 | 2-THIA-1,6,8-TRIAZA-NAPHTALENE-2,2-DIOXIDES AS CDK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1307450-A2 | 2-(4-PYRDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO(2.3-D)PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1300405-A1 | AMINO ALCOHOL DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002012238-A2 | 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY (US) | 2002-02-14 | — | — | WO | disclosed |